Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue

Molecular drugs targeting mutated or rearranged oncogene drivers have become one of the standard recognized treatments in patients with advanced and recurrent non-small cell lung cancer. RET is located in the long arm of human chromosome 10 and encodes a receptor tyrosine kinase protein, and RET fus...

Descripción completa

Detalles Bibliográficos
Autores principales: Takamori, Shinkichi, Matsubara, Taichi, Haratake, Naoki, Toyokawa, Gouji, Fujishita, Takatoshi, Toyozawa, Ryo, Ito, Kensaku, Yamaguchi, Masafumi, Taguchi, Kenichi, Okamoto, Tatsuro, Seto, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419300/
https://www.ncbi.nlm.nih.gov/pubmed/34497761
http://dx.doi.org/10.3389/fonc.2021.704084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419300/
https://www.ncbi.nlm.nih.gov/pubmed/34497761
http://dx.doi.org/10.3389/fonc.2021.704084

Ejemplares similares